ReviewCureus2025
Efficacy of Blinatumomab in Pediatric Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blinatumomab, a bispecific T-cell engager antibody, has emerged as a promising immunotherapeutic agent for pediatric acute lymphoblastic leukemia (ALL), yet comprehensive evidence regarding its efficacy remains limited. This systematic review and meta-analysis aimed to evaluate the therapeutic outcomes of blinatumomab in children with ALL. A comprehensive literature search was conducted across PubMed, EMBASE, Web of Science, and Cochrane Library databases from inception to May 2025, using terms related to blinatumomab, ALL, and pediatric populations. Studies comparing blinatumomab with chemotherapy or placebo in children and adolescents with B-cell ALL were included. Three randomized controlled trials met the inclusion criteria and were analyzed using random-effects models. Quality assessment was performed using the Cochrane Risk of Bias Tool (RoB 2, Cochrane Collaboration, London, UK). The meta-analysis demonstrated significantly superior outcomes with blinatumomab compared to chemotherapy alone. Overall survival was significantly higher in the blinatumomab group, with an odds ratio of 1.90 (95% CI: 1.28-2.82). Event-free survival showed even greater improvement with an odds ratio of 2.97 (95% CI: 2.13-4.13). Additionally, the cumulative incidence of relapse was substantially lower in patients receiving blinatumomab, with an odds ratio of 0.26 (95% CI: 0.18-0.39). No evidence of heterogeneity was observed across studies for any outcome measure. These findings suggest that blinatumomab offers significant therapeutic advantages over conventional chemotherapy in pediatric patients with ALL, providing improved survival outcomes and reduced relapse rates. The results support the integration of blinatumomab into treatment protocols for children with ALL, particularly those at high risk of relapse or with refractory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.